These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18945928)

  • 1. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).
    Le Floch JP; Lévy M; Mosnier-Pudar H; Nobels F; Laroche S; Gonbert S; Eschwege E; Fontaine P;
    Diabetes Care; 2009 Jan; 32(1):32-7. PubMed ID: 18945928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R; Lebenthal Y; Shalitin S; Benzaquen H; Demol S; Phillip M
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.
    Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
    Diabet Med; 2013 Feb; 30(2):216-25. PubMed ID: 23094597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
    Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
    Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.
    Lundby-Christensen L; Vaag A; Tarnow L; Almdal TP; Lund SS; Wetterslev J; Gluud C; Boesgaard TW; Wiinberg N; Perrild H; Krarup T; Snorgaard O; Gade-Rasmussen B; Thorsteinsson B; Røder M; Mathiesen ER; Jensen T; Vestergaard H; Hedetoft C; Breum L; Duun E; Sneppen SB; Pedersen O; Hemmingsen B; Carstensen B; Madsbad S
    BMJ Open; 2016 Feb; 6(2):e008377. PubMed ID: 26916685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
    Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
    Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
    Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
    Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E; Lang H; Roberts A
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
    Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.
    Thalange N; Deeb L; Iotova V; Kawamura T; Klingensmith G; Philotheou A; Silverstein J; Tumini S; Ocampo Francisco AM; Kinduryte O; Danne T
    Pediatr Diabetes; 2015 May; 16(3):164-76. PubMed ID: 25683037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S; Dizdar OS; Oz Gul O; Guclu M; Unal OK; Tuncel E; Erturk E; Imamoglu S; Ersoy C
    Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial.
    Davies M; Sasaki T; Gross JL; Bantwal G; Ono Y; Nishida T; Tojjar D; Seino H
    Diabetes Obes Metab; 2016 Jan; 18(1):96-9. PubMed ID: 26435472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
    Bartley PC; Bogoev M; Larsen J; Philotheou A
    Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
    Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study.
    Shanmugasundar G; Bhansali A; Walia R; Dutta P; Upreti V
    Indian J Med Res; 2012; 135(1):78-83. PubMed ID: 22382187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial.
    Mathiesen ER; Alibegovic AC; Corcoy R; Dunne F; Feig DS; Hod M; Jia T; Kalyanam B; Kar S; Kautzky-Willer A; Marchesini C; Rea RD; Damm P;
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):86-95. PubMed ID: 36623517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
    Abalı S; Turan S; Atay Z; Güran T; Haliloğlu B; Bereket A
    Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.